Cash Flow Statement

Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Growth Metrics

Others

Ratios

Gain Therapeutics (GANX) Change in Working Capital (2020 - 2021)

Gain Therapeutics has reported Change in Working Capital over the past 2 years, most recently at $1.4 million for Q4 2021.

Quarterly results put Change in Working Capital at $1.4 million for Q4 2021, up 617.86% from a year ago — trailing twelve months through Dec 2021 was $329784.0 (up 233.94% YoY), and the annual figure for FY2021 was $329784.0, up 233.94%.
Change in Working Capital for Q4 2021 was $1.4 million at Gain Therapeutics, up from -$1.7 million in the prior quarter.
Over the last five years, Change in Working Capital for GANX hit a ceiling of $1.4 million in Q4 2021 and a floor of -$1.7 million in Q3 2021.